Text Size
815 studies found for:    "Fluarix"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.
Condition: Influenza
Interventions: Biological: Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation;   Biological: Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation
2 Completed
Has Results 		Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects
Conditions: Influenza;   Myxovirus Infection
Intervention: Biological: Split, Inactivated, Trivalent Influenza Vaccine
3 Completed
Has Results 		Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM
Condition: Influenza
Intervention: Biological: Influenza Virus Vaccine USP Trivalent Types A and B
4 Completed
Has Results 		Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.
Condition: Influenza
Intervention: Biological: Influenza Virus Vaccine, Fluzone®
5 Completed
Has Results 		Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults
Condition: Influenza
Interventions: Biological: Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation;   Biological: Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation
6 Completed Study of Quadrivalent Influenza Vaccine Among Adults
Condition: Influenza
Interventions: Biological: Quadrivalent Inactivated Influenza Vaccine, No Preservative;   Biological: Trivalent Inactivated Influenza Vaccine;   Biological: Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine
7 Completed
Has Results 		Influenza Vaccine Revaccination in Ambulatory Elderly Subjects
Conditions: Influenza;   Orthomyxovirus Infection;   Myxovirus Infection
Intervention: Biological: Influenza Virus Vaccine USP Trivalent Types A and B
8 Completed Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)
Condition: Influenza
Interventions: Biological: Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose;   Biological: Fluzone®; Influenza Virus Vaccine, No Preservative
9 Completed
Has Results 		Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine
Condition: Influenza
Intervention: Biological: Influenza Virus Vaccine (Fluzone®)
10 Completed
Has Results 		Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Conditions: Orthomyxoviridae Infection;   Influenza;   Myxovirus Infection
Interventions: Biological: High-Dose Inactivated, Split-Virion Influenza Vaccine;   Biological: Inactivated, Split-Virion Influenza Vaccine
11 Unknown † FluMist in Egg Allergic Patients
Conditions: Egg Allergy;   Eligible for Vaccination Against Influenza
Interventions: Biological: FluMist intranasal influenza vaccine;   Biological: Intramuscular influenza injection ("flu shot")
12 Completed
Has Results 		Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children
Conditions: Orthomyxoviridae Infection;   Influenza;   Myxovirus Infection
Interventions: Biological: Split, Inactivated, Trivalent Influenza Vaccine;   Biological: Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)
13 Completed
Has Results 		Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine
Condition: Influenza
Intervention: Biological: Fluzone®: Influenza virus vaccine 2004-2005 formulation
14 Completed Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant
Condition: Influenza
Interventions: Biological: Fluzone vaccine with JVRS-100 adjuvant;   Biological: Fluzone vaccine
15 Completed
Has Results 		Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over
Condition: Influenza Infection
Interventions: Biological: GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season];   Biological: GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season];   Biological: Fluarix [NH 2006/07 season];   Biological: Fluarix [NH 2007/08 season]
16 Completed
Has Results 		Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old
Condition: Influenza
Interventions: Biological: Lot A of Influenza virus vaccine;   Biological: Lot B of Influenza virus vaccine;   Biological: Lot C of Influenza virus vaccine;   Biological: Comparator influenza virus vaccine;   Biological: All 3 consecutive lots of influenza virus vaccine pooled
17 Completed
Has Results 		Trial to Collect Safety Data and Sera for Immunogenicity Testing
Condition: Influenza
Intervention: Biological: Influenza Virus Vaccine (Fluzone®)
18 Completed
Has Results 		Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults
Conditions: Orthomyxoviridae Infection;   Influenza;   Myxovirus Infection
Intervention: Biological: Influenza Virus Vaccine USP Trivalent Types A and B
19 Active, not recruiting Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years
Condition: Influenza
Interventions: Biological: Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation;   Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal;   Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal
20 Active, not recruiting A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults
Condition: Influenza
Interventions: Biological: High Dose Trivalent Inactivated Influenza Vaccine;   Biological: Trivalent Inactivated Influenza Vaccine
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years